ebooks logo journals logo reference works logo abstract databases logo
bullet  SIGN IN Register | Why Register? | Got a Voucher? alerts   marked lists   shopping cart 
Advert: Informa Healthcare - http://www.informahealthcare.com

informaworld

HOME   |   SEARCH   |   BROWSE
    Issues List       Latest Issue       Forthcoming Articles       Volume 23 Issue 5       Subscribe       Article       References       Related articles      
<< firstfirst   < prevprev   Table of contentstoc   next >next   last >>last
Publisher Logo Publication Cover
Search within this journal

Polycystic ovary syndrome and hyperprolactinemia are distinct entities 

Authors: Roberpaulo Barboza Filho a;  Lucilia Domingues b;  Luciana Naves c;  Elenice Ferraz b;  Adriana Alves c; Luiz Augusto Casulari c
Affiliations:   a Endocrinology and Neurology Clinics - CLINEN, Brasiacutelia, Brazil
b Department of Obstetrics and Gynecology, University of Brasiacutelia, Brasiacutelia, Brazil
c Endocrinology Service, University of Brasiacutelia, Brasiacutelia, Brazil
DOI: 10.1080/09513590701297708
Publication Frequency: 12 issues per year
Published in: journal Gynecological Endocrinology, Volume 23, Issue 5 May 2007 , pages 267 - 272
Formats available: HTML (English) : PDF (English)
Article Requests: Order Reprints : Request Permissions


Abstract

The aims of the present study were to identify the cause of hyperprolactinemia in polycystic ovary syndrome (PCOS) and to compare prolactin (PRL) levels between PCOS women without hyperprolactinemia and women with insulin resistance and without PCOS. A group of 82 women (age: 27.1 ± 7.6 years) with PCOS was included in the study. Their PRL levels were measured and compared with those of women with insulin resistance without PCOS (controls; n = 42; age: 29.2 ± 8.2 years). Among the 82 PCOS women, 13 (16%) presented high PRL levels (103.9 ± 136.0 μg/l). The causes of hyperprolactinemia were: pituitary tumor (responding to cabergoline) in nine cases (69%; PRL range: 28.6 - 538 μg/l); oral hormonal contraceptive treatment in two cases (15%; PRL: 46 and 55 μg/l, respectively); and use of buspirone and tianeptine in one case (8%; PRL: 37.1 μg/l); one case (8%; PRL: 34.4 μg/l) had macroprolactinemia. In drug-induced hyperprolactinemic patients PRL levels normalized after treatment interruption. The average PRL level in the 69 remaining patients was 12.1 ± 5.5 μg/l, a value not statistically different from that of the control group (11.8 ± 4.9 μg/l). This result leads us to conclude that PCOS patients with increased PRL levels must be investigated for other causes of hyperprolactinemia, because hyperprolactinemia is not a clinical manifestation of PCOS.
Keywords: Hyperprolactinemia; polycystic ovary syndrome; insulin resistance; ovary; macroprolactinemia
view references (61)
Bookmark with:
  • CiteULike
  • Del.icio.us
  • BibSonomy
  • Connotea
  • More bookmarks
Privacy Policy | Terms & Conditions | Accessibility | RSS
FAQs in: English . Français . Español . 中文(简体和繁體)
© 2009 Informa plc